Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice
复制标题
DOI：
10.1176/appi.ajp.163.1.28
复制
发表时间：
2006-01-01
影响因子：
17.7
通讯作者：
Fava, M
中科院分区：
文献类型：
--
作者：
Trivedi, MH;Rush, AJ;Fava, M
目的：选择性5-羟色胺再摄取抑制剂（SSRIs）被广泛用于治疗抑郁症，但在“真实的世界”患者中缓解的速率、时间和基线预测因子尚未建立。作者在这项研究中的主要目标是评估西酞普兰，SSRI，在实际工作中使用基于测量的护理的有效性，并确定在门诊患者的症状缓解的预测因子与major depression disorder.Method：本临床研究包括门诊患者与major depression disorder谁在23精神和18个初级保健“真实的世界”设置治疗。这些患者接受了临床医生处方的灵活剂量的西酞普兰治疗长达14周。临床研究协调员协助临床医生应用基于测量的护理，包括每次治疗访视时常规测量症状和副作用，以及使用治疗手册，描述何时以及如何根据这些措施修改药物剂量。缓解定义为退出评分
Objective: Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat depression, but the rates, timing, and baseline predictors of remission in "real world" patients are not established. The authors' primary objectives in this study were to evaluate the effectiveness of citalopram, an SSRI, using measurement-based care in actual practice, and to identify predictors of symptom remission in outpatients with major depressive disorder.Method: This clinical study included outpatients with major depressive disorder who were treated in 23 psychiatric and 18 primary care " real world" settings. The patients received flexible doses of citalopram prescribed by clinicians for up to 14 weeks. The clinicians were assisted by a clinical research coordinator in the application of measurement-based care, which included the routine measurement of symptoms and side effects at each treatment visit and the use of a treatment manual that described when and how to modify medication doses based on these measures. Remission was defined as an exit score of